ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Supernus Pharmaceuticals, Inc. clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 86 studies whose lead sponsor is Supernus Pharmaceuticals, Inc. or one of 4 companies grouped under it. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 17, 2026.

Our grouping of 5 registry names, not the registry’s. See them and correct one ↓

Compare Supernus Pharmaceuticals with Johnson & Johnson and CSPC Pharmaceutical Group →

Pipeline: 2 programs

Each counted once: 2 with a study Supernus Pharmaceuticals, Inc. leads registered in the last two years.

  • Phase 2

The 2 programs — sign in to see the list, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Supernus Pharmaceuticals, Inc.’s own registered studies; Supernus Pharmaceuticals, Inc.’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Supernus Pharmaceuticals, Inc.’s studies test, most open studies first — 14 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 4 more

Coming up

5 of Supernus Pharmaceuticals, Inc.’s studies under way reach primary completion within a year, 1 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. 3D
  3. J’27
  4. F
  5. M
  6. A
  7. M
  8. J
  9. J
  10. 2A
  11. S
  12. O
  13. N

Add all 5 to your calendar (.ics) → With an account.

All 86 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now67%Recruiting 5 · Enrolling by invitation 1
  • Under way, not recruiting33%
  • Completed5969%
  • Stopped early1517%Terminated 12 · Withdrawn 3
  • Status unknown or other33%Approved for marketing 2 · No longer available 1

Phase

  • Phase 333
  • Phase 231
  • Phase 114
  • Phase 49
  • Early Phase 11

Where

  • United States76
  • Canada13
  • Australia9
  • Spain5
  • Germany5
  • France5

Over the years

  1. 08
  2. 09
  3. 10
  4. 11
  5. 12
  6. 13
  7. 14
  8. 15
  9. 16
  10. 17
  11. 918
  12. 19
  13. 20
  14. 21
  15. 22
  16. 23
  17. 24
  18. 25
  19. 126

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Supernus Pharmaceuticals, Inc.

  • Supernus Pharmaceuticals, Inc.
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    64 studies
  • Adamas Pharmaceuticals, Inc.
    Acquired — became part of Supernus Pharmaceuticals, Inc., Nov 24, 2021 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    10 studies →
  • Sage Therapeutics
    Acquired — became part of Supernus Pharmaceuticals, Inc., Jul 31, 2025 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    6 studies →
  • MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
    Acquired — became part of Supernus Pharmaceuticals, Inc., Jun 9, 2020 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    3 studies →
  • Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
    Acquired — became part of Supernus Pharmaceuticals, Inc., Jun 9, 2020 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    3 studies →

Focus areas

Conditions Supernus Pharmaceuticals, Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 86. Browse all 86 →